Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Top Cited Papers
Open Access
- 1 October 2012
- journal article
- practice guideline
- Published by Elsevier BV in Annals of Oncology
- Vol. 23 (suppl_7), vii65-vii71
- https://doi.org/10.1093/annonc/mds227
Abstract
Renal cell carcinoma (RCC) accounts for 2%–3% of all adult malignancies, representing the seventh most common cancer in men and the ninth most common cancer in women [1]. Worldwide, there are ∼209 000 new cases and 102 000 deaths per year. The incidence of all stages of RCC has increased over the past several years, contributing to a steadily increasing mortality rate per unit population. Active and passive cigarette smoking is an established risk factor for RCC as well as hypertension. However, anti-hypertensive medications such as diuretics are not independently associated with RCC development. RCC also appears to be more common in patients with obesity, end-stage renal failure, acquired renal cystic disease and tuberous sclerosis.This publication has 20 references indexed in Scilit:
- Long-Term Outcomes of Renal Tumor Radio Frequency Ablation Stratified by Tumor Diameter: Size MattersJournal of Urology, 2012
- Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trialThe Lancet, 2011
- Growth Kinetics of Renal Masses: Analysis of a Prospective Cohort of Patients Undergoing Active SurveillanceEuropean Urology, 2011
- Metastasectomy After Targeted Therapy in Patients With Advanced Renal Cell CarcinomaJournal of Urology, 2011
- Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III TrialJournal of Clinical Oncology, 2010
- Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter StudyJournal of Clinical Oncology, 2009
- Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trialThe Lancet, 2008
- Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trialThe Lancet, 2008
- Sorafenib in Advanced Clear-Cell Renal-Cell CarcinomaThe New England Journal of Medicine, 2007
- Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinomaCancer, 2003